汇宇制药(688553.SH)：注射用HY05350I期临床试验首例受试者给药

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., has initiated a Phase I clinical trial for its innovative biological drug, HY05350, aimed at treating advanced solid tumors, with the first patient successfully dosed [1]. Group 1 - The drug HY05350 has received approval from the National Medical Products Administration for clinical trials [1]. - The clinical study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary clinical efficacy of HY05350 in patients with MSLN-positive advanced solid tumors [1]. - The primary objective of the study is to assess the safety and tolerability of HY05350 as a monotherapy during the dose escalation phase, explore the maximum tolerated dose (MTD), and provide recommended doses (RP2D) for subsequent clinical research [1].